Calamos Advisors LLC Grows Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Calamos Advisors LLC increased its position in Amedisys, Inc. (NASDAQ:AMED) by 22.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 487,444 shares of the health services provider’s stock after purchasing an additional 90,097 shares during the period. Calamos Advisors LLC owned approximately 1.49% of Amedisys worth $44,255,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC purchased a new stake in shares of Amedisys during the 4th quarter worth approximately $38,000. Versant Capital Management Inc raised its stake in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV acquired a new stake in shares of Amedisys during the 3rd quarter valued at approximately $63,000. Finally, Signaturefd LLC raised its holdings in Amedisys by 20.9% in the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after acquiring an additional 236 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Down 0.4 %

Shares of Amedisys stock opened at $92.15 on Tuesday. The company has a market capitalization of $3.02 billion, a PE ratio of 36.57, a P/E/G ratio of 1.82 and a beta of 0.73. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The business has a 50-day moving average of $89.43 and a 200-day moving average of $93.92. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $587.67 million for the quarter, compared to the consensus estimate of $586.75 million. During the same quarter in the prior year, the firm posted $0.98 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, equities analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.